FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2019-05-03
Target enrollment:
Participant gender:
Summary
This study will enroll patients who have metastatic pancreatic cancer with stable disease on
FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between
patients that receive ipilimumab and a pancreatic tumor vaccine and patients who continue to
receive FOLFIRINOX.
Funding Source - FDA Office of Orphan Product Development (OOPD)
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins